{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:41Z","timestamp":1787002661129,"version":"build-2736575974"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R00 045765"],"award-info":[{"award-number":["R00 045765"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 061303"],"award-info":[{"award-number":["R01 061303"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31DA059203"],"award-info":[{"award-number":["F31DA059203"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA045836"],"award-info":[{"award-number":["R01 DA045836"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005355","name":"American Australian Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005355","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03571-5","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:21:13Z","timestamp":1761319273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Found in translation: orexin receptor antagonism for the treatment of opioid use disorder"],"prefix":"10.1038","volume":"15","author":[{"given":"Joel S.","family":"Raymond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin D.","family":"Vareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-8607","authenticated-orcid":false,"given":"Morgan H.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"3571_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","volume":"3","author":"KM Keyes","year":"2022","unstructured":"Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052.","journal-title":"Drug Alcohol Depend Rep"},{"key":"3571_CR2","doi-asserted-by":"publisher","unstructured":"Ahmad FB, Anderson RN, Cisewski JA, Rossen LM, Sutton P. County-level provisional drug overdose death counts. National Centerfor Health Statistics. 2025. https:\/\/doi.org\/10.15620\/cdc\/20250305009..","DOI":"10.15620\/cdc\/20250305009"},{"key":"3571_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3389\/fpsyt.2018.00742","volume":"9","author":"F Noble","year":"2018","unstructured":"Noble F, Marie N. Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine. Front Psychiatry. 2018;9:742. https:\/\/doi.org\/10.3389\/fpsyt.2018.00742","journal-title":"Front Psychiatry"},{"key":"3571_CR4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tins.2021.09.002","volume":"44","author":"JB Mehr","year":"2021","unstructured":"Mehr JB, Bilotti MM, James MH. Orexin (hypocretin) and addiction. Trends Neurosci. 2021;44:852\u20135. https:\/\/doi.org\/10.1016\/j.tins.2021.09.002","journal-title":"Trends Neurosci"},{"key":"3571_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","volume":"44","author":"JE Fragale","year":"2019","unstructured":"Fragale JE, Pantazis CB, James MH, Aston-Jones G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology. 2019;44:1690\u20137. https:\/\/doi.org\/10.1038\/s41386-019-0420-x","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR6","doi-asserted-by":"publisher","first-page":"9831","DOI":"10.1523\/jneurosci.0255-19.2019","volume":"39","author":"A Mohammadkhani","year":"2019","unstructured":"Mohammadkhani A, Fragale JE, Pantazis CB, Bowrey HE, James MH, Aston-Jones G. Orexin-1 receptor signaling in ventral pallidum regulates motivation for the opioid remifentanil. J Neurosci. 2019;39:9831\u201340. https:\/\/doi.org\/10.1523\/jneurosci.0255-19.2019","journal-title":"J Neurosci"},{"key":"3571_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nn.3810","volume":"17","author":"SV Mahler","year":"2014","unstructured":"Mahler SV, Moorman DE, Smith RJ, James MH, Aston-Jones G. Motivational activation: a unifying hypothesis of orexin\/hypocretin function. Nat Neurosci. 2014;17:1298\u2013303. https:\/\/doi.org\/10.1038\/nn.3810","journal-title":"Nat Neurosci"},{"key":"3571_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.biopsych.2022.06.027","volume":"92","author":"MH James","year":"2022","unstructured":"James MH, Aston-Jones G. Orexin reserve: a mechanistic framework for the role of orexins (Hypocretins) in addiction. Biol Psychiatry. 2022;92:836\u201344. https:\/\/doi.org\/10.1016\/j.biopsych.2022.06.027","journal-title":"Biol Psychiatry"},{"key":"3571_CR9","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1523\/JNEUROSCI.23-08-03106.2003","volume":"23","author":"D Georgescu","year":"2003","unstructured":"Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci. 2003;23:3106\u201311.","journal-title":"J Neurosci"},{"key":"3571_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.biopsych.2008.03.006","volume":"64","author":"R Sharf","year":"2008","unstructured":"Sharf R, Sarhan M, Dileone RJ. Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. Biol Psychiatry. 2008;64:175\u201383. https:\/\/doi.org\/10.1016\/j.biopsych.2008.03.006","journal-title":"Biol Psychiatry"},{"key":"3571_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02161-z","volume":"12","author":"G Giannotti","year":"2022","unstructured":"Giannotti G, Mottarlini F, Heinsbroek JA, Mandel MR, James MH, Peters J. Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking. Transl Psychiatry. 2022;12:432. https:\/\/doi.org\/10.1038\/s41398-022-02161-z","journal-title":"Transl Psychiatry"},{"key":"3571_CR12","doi-asserted-by":"crossref","unstructured":"O\u2019Connor, SL, Fragale, JE, James, MH, Aston-Jones, G The dual orexin\/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl. 2020. bioRxiv: 2020.2004.2025.061887.","DOI":"10.1101\/2020.04.25.061887"},{"key":"3571_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40263-014-0179-x","volume":"28","author":"SY Khoo","year":"2014","unstructured":"Khoo SY, Brown RM. Orexin\/Hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs. 2014;28:713\u201330. https:\/\/doi.org\/10.1007\/s40263-014-0179-x","journal-title":"CNS Drugs"},{"key":"3571_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41386-022-01404-3","volume":"48","author":"U Gyawali","year":"2023","unstructured":"Gyawali U, James MH. Sleep disturbance in substance use disorders: the orexin (hypocretin) system as an emerging pharmacological target. Neuropsychopharmacology. 2023;48:228\u20139. https:\/\/doi.org\/10.1038\/s41386-022-01404-3","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41386-020-0619-x","volume":"45","author":"MH James","year":"2020","unstructured":"James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology. 2020;45:717\u20139. https:\/\/doi.org\/10.1038\/s41386-020-0619-x","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00213-023-06320-y","volume":"240","author":"M Moline","year":"2023","unstructured":"Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J, et al. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology. 2023;240:699\u2013711. https:\/\/doi.org\/10.1007\/s00213-023-06320-y","journal-title":"Psychopharmacology"},{"key":"3571_CR17","first-page":"140","volume":"12","author":"HR Fathi","year":"2020","unstructured":"Fathi HR, Yoonessi A, Khatibi A, Rezaeitalab F, Rezaei-Ardani A. Crosstalk between sleep disturbance and opioid use disorder: a narrative review. Addict Health. 2020;12:140.","journal-title":"Addict Health"},{"key":"3571_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","volume":"44","author":"K Rasmussen","year":"2019","unstructured":"Rasmussen K, White DA, Acri JB. NIDA\u2019s medication development priorities in response to the opioid crisis: ten most wanted. Neuropsychopharmacology. 2019;44:657\u20139. https:\/\/doi.org\/10.1038\/s41386-018-0292-5","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn8238","volume":"14","author":"AS Huhn","year":"2022","unstructured":"Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, et al. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med. 2022;14:eabn8238. https:\/\/doi.org\/10.1126\/scitranslmed.abn8238","journal-title":"Sci Transl Med"},{"key":"3571_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae025","volume":"47","author":"MJ Reid","year":"2024","unstructured":"Reid MJ, Dunn KE, Abraham L, Ellis J, Hunt C, Gamaldo CE, et al. Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal. Sleep. 2024;47:zsae025.","journal-title":"Sleep"},{"key":"3571_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/pharmrev.123.000953","volume":"76","author":"JP Kukkonen","year":"2024","unstructured":"Kukkonen JP, Jacobson LH, Hoyer D, Rinne MK, Borgland SL, Ohlstein E. International union of basic and clinical pharmacology CXIV: orexin receptor function, nomenclature and pharmacology. Pharmacol Rev. 2024;76:625\u201388.","journal-title":"Pharmacol Rev"},{"key":"3571_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/brainsci10040226","volume":"10","author":"A Matzeu","year":"2020","unstructured":"Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder. Brain Sci. 2020;10:226.","journal-title":"Brain Sci"},{"key":"3571_CR23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bph.12639","volume":"172","author":"C Baimel","year":"2015","unstructured":"Baimel C, Bartlett SE, Chiou LC, Lawrence AJ, Muschamp JW, Patkar O, et al. Orexin\/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol. 2015;172:334\u201348.","journal-title":"Br J Pharmacol"},{"key":"3571_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40429-024-00598-4","volume":"11","author":"CJ Mun","year":"2024","unstructured":"Mun CJ, Reid MJ, Sarandos S, Elam KK, Li CM, Strickland JC. Improving sleep to address Co-Occurring substance use disorder and chronic pain: exploring the potential of the orexin (Hypocretin) system as a clinical target. Curr Addict Rep. 2024;11:1\u201313.","journal-title":"Curr Addict Rep"},{"key":"3571_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573\u201385. https:\/\/doi.org\/10.1016\/s0092-8674(00)80949-6","journal-title":"Cell"},{"key":"3571_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322\u20137. https:\/\/doi.org\/10.1073\/pnas.95.1.322","journal-title":"Proc Natl Acad Sci USA"},{"key":"3571_CR27","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996\u201310015.","journal-title":"J Neurosci"},{"key":"3571_CR28","doi-asserted-by":"publisher","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","volume":"96","author":"JJ Hagan","year":"1999","unstructured":"Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 1999;96:10911\u20136. https:\/\/doi.org\/10.1073\/pnas.96.19.10911","journal-title":"Proc Natl Acad Sci USA"},{"key":"3571_CR29","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.1523\/JNEUROSCI.20-20-07760.2000","volume":"20","author":"P Bourgin","year":"2000","unstructured":"Bourgin P, Huitron-Resendiz S, Spier AD, Fabre V, Morte B, Criado JR, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci. 2000;20:7760\u20135. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-20-07760.2000","journal-title":"J Neurosci"},{"key":"3571_CR30","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.1523\/JNEUROSCI.22-21-09453.2002","volume":"22","author":"RJ Liu","year":"2002","unstructured":"Liu RJ, van den Pol AN, Aghajanian GK. Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci. 2002;22:9453\u201364.","journal-title":"J Neurosci"},{"key":"3571_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1748-1716.2009.02036.x","volume":"198","author":"E Arrigoni","year":"2010","unstructured":"Arrigoni E, Mochizuki T, Scammell TE. Activation of the basal forebrain by the orexin\/hypocretin neurones. Acta Physiol. 2010;198:223\u201335. https:\/\/doi.org\/10.1111\/j.1748-1716.2009.02036.x","journal-title":"Acta Physiol"},{"key":"3571_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cne.1190","volume":"435","author":"JN Marcus","year":"2001","unstructured":"Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6\u201325.","journal-title":"J Comp Neurol"},{"key":"3571_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.tins.2006.08.002","volume":"29","author":"GC Harris","year":"2006","unstructured":"Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006;29:571\u20137. https:\/\/doi.org\/10.1016\/j.tins.2006.08.002","journal-title":"Trends Neurosci"},{"key":"3571_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/7854_2016_57","volume":"33","author":"MH James","year":"2017","unstructured":"James MH, Mahler SV, Moorman DE, Aston-Jones G. A decade of Orexin\/Hypocretin and addiction: where are we now? Curr Top Behav Neurosci. 2017;33:247\u201381. https:\/\/doi.org\/10.1007\/7854_2016_57","journal-title":"Curr Top Behav Neurosci"},{"key":"3571_CR35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41386-021-01173-5","volume":"47","author":"CB Pantazis","year":"2022","unstructured":"Pantazis CB, James MH, O\u2019Connor S, Shin N, Aston-Jones G. Orexin-1 receptor signaling in ventral tegmental area mediates cue-driven demand for cocaine. Neuropsychopharmacology. 2022;47:741\u201351.","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00429-011-0343-8","volume":"217","author":"O Schmitt","year":"2012","unstructured":"Schmitt O, Usunoff KG, Lazarov NE, Itzev DE, Eipert P, Rolfs A, et al. Orexinergic innervation of the extended amygdala and basal ganglia in the rat. Brain Struct Funct. 2012;217:233\u201356.","journal-title":"Brain Struct Funct"},{"key":"3571_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1037\/a0031442","volume":"127","author":"DH Arendt","year":"2013","unstructured":"Arendt DH, Ronan PJ, Oliver KD, Callahan LB, Summers TR, Summers CH. Depressive behavior and activation of the orexin\/hypocretin system. Behav Neurosci. 2013;127:86.","journal-title":"Behav Neurosci"},{"key":"3571_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5664\/jcsm.9638","volume":"18","author":"K Maski","year":"2022","unstructured":"Maski K, Mignot E, Plazzi G, Dauvilliers Y. Disrupted nighttime sleep and sleep instability in narcolepsy. J Clin Sleep Med. 2022;18:289\u2013304.","journal-title":"J Clin Sleep Med"},{"key":"3571_CR39","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1523\/JNEUROSCI.0586-04.2004","volume":"24","author":"T Mochizuki","year":"2004","unstructured":"Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci. 2004;24:6291\u20136300.","journal-title":"J Neurosci"},{"key":"3571_CR40","doi-asserted-by":"publisher","first-page":"e0178573","DOI":"10.1371\/journal.pone.0178573","volume":"12","author":"R McGregor","year":"2017","unstructured":"McGregor R, Shan L, Wu M-F, Siegel JM. Diurnal fluctuation in the number of hypocretin\/orexin and histamine producing: implication for understanding and treating neuronal loss. PLoS One. 2017;12:e0178573.","journal-title":"PLoS One"},{"key":"3571_CR41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature04071","volume":"437","author":"GC Harris","year":"2005","unstructured":"Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005;437:556\u20139. https:\/\/doi.org\/10.1038\/nature04071","journal-title":"Nature"},{"key":"3571_CR42","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1523\/JNEUROSCI.3917-11.2012","volume":"32","author":"KA Richardson","year":"2012","unstructured":"Richardson KA, Aston-Jones G. Lateral hypothalamic orexin\/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference. J Neurosci. 2012;32:3809\u201317. https:\/\/doi.org\/10.1523\/JNEUROSCI.3917-11.2012","journal-title":"J Neurosci"},{"key":"3571_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bbr.2007.05.025","volume":"183","author":"GC Harris","year":"2007","unstructured":"Harris GC, Wimmer M, Randall-Thompson JF, Aston-Jones G. Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behav Brain Res. 2007;183:43\u201351. https:\/\/doi.org\/10.1016\/j.bbr.2007.05.025","journal-title":"Behav Brain Res"},{"key":"3571_CR44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.brainres.2009.12.035","volume":"1317","author":"R Sharf","year":"2010","unstructured":"Sharf R, Guarnieri DJ, Taylor JR, DiLeone RJ. Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Res. 2010;1317:24\u201332.","journal-title":"Brain Res"},{"key":"3571_CR45","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1523\/JNEUROSCI.2761-05.2006","volume":"26","author":"M Narita","year":"2006","unstructured":"Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci. 2006;26:398\u2013405.","journal-title":"J Neurosci"},{"key":"3571_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2017.09.007","volume":"660","author":"MM Alizamini","year":"2017","unstructured":"Alizamini MM, Farzinpour Z, Ezzatpanah S, Haghparast A. Role of intra-accumbal orexin receptors in the acquisition of morphine-induced conditioned place preference in the rats. Neurosci Lett. 2017;660:1\u20135.","journal-title":"Neurosci Lett"},{"key":"3571_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.npep.2017.08.003","volume":"66","author":"S Farahimanesh","year":"2017","unstructured":"Farahimanesh S, Zarrabian S, Haghparast A. Role of orexin receptors in the ventral tegmental area on acquisition and expression of morphine-induced conditioned place preference in the rats. Neuropeptides. 2017;66:45\u201351.","journal-title":"Neuropeptides"},{"key":"3571_CR48","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00213-016-4280-3","volume":"233","author":"B Sadeghi","year":"2016","unstructured":"Sadeghi B, Ezzatpanah S, Haghparast A. Effects of dorsal hippocampal orexin-2 receptor antagonism on the acquisition, expression, and extinction of morphine-induced place preference in rats. Psychopharmacology. 2016;233:2329\u201341.","journal-title":"Psychopharmacology"},{"key":"3571_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pbb.2015.12.005","volume":"142","author":"F Sadeghzadeh","year":"2016","unstructured":"Sadeghzadeh F, Namvar P, Naghavi FS, Haghparast A. Differential effects of intra-accumbal orexin-1 and-2 receptor antagonists on the expression and extinction of morphine-induced conditioned place preference in rats. Pharmacol Biochem Behav. 2016;142:8\u201314.","journal-title":"Pharmacol Biochem Behav"},{"key":"3571_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.peptides.2017.12.017","volume":"101","author":"S Farahimanesh","year":"2018","unstructured":"Farahimanesh S, Karimi S, Haghparast A. Role of orexin-1 receptors in the dorsal hippocampus (CA1 region) in expression and extinction of the morphine-induced conditioned place preference in the rats. Peptides. 2018;101:25\u201331.","journal-title":"Peptides"},{"key":"3571_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1037\/bne0000112","volume":"130","author":"F Ebrahimian","year":"2016","unstructured":"Ebrahimian F, Naghavi FS, Yazdi F, Sadeghzadeh F, Taslimi Z, Haghparast A. Differential roles of orexin receptors within the dentate gyrus in stress-and drug priming-induced reinstatement of conditioned place preference in rats. Behav Neurosci. 2016;130:91.","journal-title":"Behav Neurosci"},{"key":"3571_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12946","volume":"26","author":"JE Fragale","year":"2021","unstructured":"Fragale JE, James MH, Aston-Jones G. Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addict Biol. 2021;26:e12946. https:\/\/doi.org\/10.1111\/adb.12946","journal-title":"Addict Biol"},{"key":"3571_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/adb.12323","volume":"22","author":"KA Porter-Stransky","year":"2017","unstructured":"Porter-Stransky KA, Bentzley BS, Aston-Jones G. Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil. Addiction Biol. 2017;22:303\u201317. https:\/\/doi.org\/10.1111\/adb.12323","journal-title":"Addiction Biol"},{"key":"3571_CR54","doi-asserted-by":"publisher","first-page":"146461","DOI":"10.1016\/j.brainres.2019.146461","volume":"1731","author":"A Mohammadkhani","year":"2020","unstructured":"Mohammadkhani A, James MH, Pantazis CB, Aston-Jones G. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res. 2020;1731:146461.","journal-title":"Brain Res"},{"key":"3571_CR55","doi-asserted-by":"publisher","first-page":"e36871","DOI":"10.1371\/journal.pone.0036871","volume":"7","author":"ML Laorden","year":"2012","unstructured":"Laorden ML, Ferenczi S, Pint\u00e9r-K\u00fcbler B, Gonz\u00e1lez-Mart\u00edn LL, Lasheras MC, Kov\u00e1cs KJ, et al. Hypothalamic orexin\u2013a neurons are involved in the response of the brain stress system to morphine withdrawal. PLoS One. 2012;7:e36871. https:\/\/doi.org\/10.1371\/journal.pone.0036871","journal-title":"PLoS One"},{"key":"3571_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1677\/joe.1.06960","volume":"191","author":"Y Zhou","year":"2006","unstructured":"Zhou Y, Bendor J, Hofmann L, Randesi M, Ho A, Kreek MJ. Mu opioid receptor and orexin\/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J Endocrinol. 2006;191:137\u201345.","journal-title":"J Endocrinol"},{"key":"3571_CR57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.06.038","volume":"578","author":"Y Mousavi","year":"2014","unstructured":"Mousavi Y, Azizi H, Mirnajafi-Zadeh J, Javan M, Semnanian S. Blockade of orexin type-1 receptors in locus coeruleus nucleus attenuates the development of morphine dependency in rats. Neurosci Lett. 2014;578:90\u201394.","journal-title":"Neurosci Lett"},{"key":"3571_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.brainresbull.2017.01.010","volume":"130","author":"M Ghaemi-Jandabi","year":"2017","unstructured":"Ghaemi-Jandabi M, Azizi H, Ahmadi-Soleimani SM, Semnanian S. Intracoerulear microinjection of orexin-A induces morphine withdrawal-like signs in rats. Brain Res Bull. 2017;130:107\u201311.","journal-title":"Brain Res Bull"},{"key":"3571_CR59","doi-asserted-by":"publisher","first-page":"eaao4953","DOI":"10.1126\/scitranslmed.aao4953","volume":"10","author":"TC Thannickal","year":"2018","unstructured":"Thannickal TC, John J, Shan L, Swaab DF, Wu MF, Ramanathan L, et al. Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci Transl Med. 2018;10:eaao4953. https:\/\/doi.org\/10.1126\/scitranslmed.aao4953","journal-title":"Sci Transl Med"},{"key":"3571_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1523\/JNEUROSCI.1557-21.2021","volume":"42","author":"R McGregor","year":"2022","unstructured":"McGregor R, Wu M-F, Holmes B, Lam HA, Maidment NT, Gera J, et al. Hypocretin\/orexin interactions with norepinephrine contribute to the opiate withdrawal syndrome. J Neurosci. 2022;42:255\u201363.","journal-title":"J Neurosci"},{"key":"3571_CR61","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s44220-024-00278-2","volume":"2","author":"R McGregor","year":"2024","unstructured":"McGregor R, Wu M-F, Thannickal TC, Li S, Siegel JM. Opioid-induced neuroanatomical, microglial and behavioral changes are blocked by suvorexant without diminishing opioid analgesia. Nat Ment Health. 2024;2:1018\u201331.","journal-title":"Nat Ment Health"},{"key":"3571_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12795","volume":"25","author":"CB Pantazis","year":"2020","unstructured":"Pantazis CB, James MH, Bentzley BS, Aston-Jones G. The number of lateral hypothalamus orexin\/hypocretin neurons contributes to individual differences in cocaine demand. Addict Biol. 2020;25:e12795. https:\/\/doi.org\/10.1111\/adb.12795","journal-title":"Addict Biol"},{"key":"3571_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2020.102074","volume":"83","author":"MS Sadat-Shirazi","year":"2020","unstructured":"Sadat-Shirazi MS, Soltani H, Nikpour N, Haghshenas M, Khalifeh S, Mokri A, et al. Alteration of orexin-A and PKC\u03b1 in the postmortem brain of pure-opioid and multi-drug abusers. Neuropeptides. 2020;83:102074. https:\/\/doi.org\/10.1016\/j.npep.2020.102074","journal-title":"Neuropeptides"},{"key":"3571_CR64","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.biopsych.2018.07.022","volume":"85","author":"MH James","year":"2019","unstructured":"James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased number and activity of a lateral subpopulation of hypothalamic orexin\/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry. 2019;85:925\u201335.","journal-title":"Biol Psychiatry"},{"key":"3571_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13238","volume":"27","author":"AD Collier","year":"2022","unstructured":"Collier AD, Yasmin N, Chang GQ, Karatayev O, Khalizova N, Fam M, et al. Embryonic ethanol exposure induces ectopic Hcrt and MCH neurons outside hypothalamus in rats and zebrafish: role in ethanol\u2010induced behavioural disturbances. Addict Biol. 2022;27:e13238.","journal-title":"Addict Biol"},{"key":"3571_CR66","doi-asserted-by":"publisher","first-page":"620868","DOI":"10.3389\/fnbeh.2021.620868","volume":"15","author":"A Matzeu","year":"2021","unstructured":"Matzeu A, Martin-Fardon R. Cocaine-seeking behavior induced by orexin A administration in the posterior paraventricular nucleus of the thalamus is not long-lasting: neuroadaptation of the orexin system during cocaine abstinence. Front Behav Neurosci. 2021;15:620868.","journal-title":"Front Behav Neurosci"},{"key":"3571_CR67","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","volume":"36","author":"Y Han","year":"2020","unstructured":"Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci Bull. 2020;36:432\u201348.","journal-title":"Neurosci Bull"},{"key":"3571_CR68","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1460-9568.2012.08013.x","volume":"35","author":"RJ Smith","year":"2012","unstructured":"Smith RJ, Aston-Jones G. Orexin \/ hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci. 2012;35:798\u2013804. https:\/\/doi.org\/10.1111\/j.1460-9568.2012.08013.x","journal-title":"Eur J Neurosci"},{"key":"3571_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107906","volume":"164","author":"A Matzeu","year":"2020","unstructured":"Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder: orexin-1 receptor blockade prevents oxycodone taking and seeking in rats. Neuropharmacology. 2020;164:107906. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107906","journal-title":"Neuropharmacology"},{"key":"3571_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1127735","volume":"14","author":"JM Illenberger","year":"2023","unstructured":"Illenberger JM, Flores-Ramirez FJ, Matzeu A, Mason BJ, Martin-Fardon R. Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Front Pharmacol. 2023;14:1127735 https:\/\/doi.org\/10.3389\/fphar.2023.1127735","journal-title":"Front Pharmacol"},{"key":"3571_CR71","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/npp.2014.293","volume":"40","author":"BE Schmeichel","year":"2015","unstructured":"Schmeichel BE, Barbier E, Misra KK, Contet C, Schlosburg JE, Grigoriadis D, et al. Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats. Neuropsychopharmacology. 2015;40:1123\u20139. https:\/\/doi.org\/10.1038\/npp.2014.293","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","volume":"66","author":"NR Richardson","year":"1996","unstructured":"Richardson NR, Roberts DC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods. 1996;66:1\u201311. https:\/\/doi.org\/10.1016\/0165-0270(95)00153-0","journal-title":"J Neurosci Methods"},{"key":"3571_CR73","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00213-012-2899-2","volume":"226","author":"BS Bentzley","year":"2013","unstructured":"Bentzley BS, Fender KM, Aston-Jones G. The behavioral economics of drug self-administration: a review and new analytical approach for within-session procedures. Psychopharmacology. 2013;226:113\u201325. https:\/\/doi.org\/10.1007\/s00213-012-2899-2","journal-title":"Psychopharmacology"},{"key":"3571_CR74","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1037\/0033-295X.115.1.186","volume":"115","author":"SR Hursh","year":"2008","unstructured":"Hursh SR, Silberberg A. Economic demand and essential value. Psychol Rev. 2008;115:186.","journal-title":"Psychol Rev"},{"key":"3571_CR75","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1111\/ejn.14166","volume":"50","author":"MH James","year":"2019","unstructured":"James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin\/hypocretin-1 receptor antagonist in rats. Eur J Neurosci. 2019;50:2602\u201312. https:\/\/doi.org\/10.1111\/ejn.14166","journal-title":"Eur J Neurosci"},{"key":"3571_CR76","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1460-9568.2009.07065.x","volume":"31","author":"RA Espana","year":"2010","unstructured":"Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31:336\u201348. https:\/\/doi.org\/10.1111\/j.1460-9568.2009.07065.x","journal-title":"Eur J Neurosci"},{"key":"3571_CR77","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.neuropharm.2012.07.044","volume":"63","author":"L Zhou","year":"2012","unstructured":"Zhou L, Smith RJ, Do PH, Aston-Jones G, See RE. Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. Neuropharmacology. 2012;63:1201\u20137. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.07.044","journal-title":"Neuropharmacology"},{"key":"3571_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108359","volume":"183","author":"MH James","year":"2021","unstructured":"James MH, Fragale JE, O\u2019Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology. 2021;183:108359. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108359","journal-title":"Neuropharmacology"},{"key":"3571_CR79","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1007\/s00213-016-4393-8","volume":"233","author":"AB Kawa","year":"2016","unstructured":"Kawa AB, Bentzley BS, Robinson TE. Less is more: prolonged intermittent access cocaine self-administration produces incentive-sensitization and addiction-like behavior. Psychopharmacology. 2016;233:3587\u2013602. https:\/\/doi.org\/10.1007\/s00213-016-4393-8","journal-title":"Psychopharmacology"},{"key":"3571_CR80","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41386-019-0571-9","volume":"45","author":"TJ O\u2019Neal","year":"2020","unstructured":"O\u2019Neal TJ, Nooney MN, Thien K, Ferguson SM. Chemogenetic modulation of accumbens direct or indirect pathways bidirectionally alters reinstatement of heroin-seeking in high- but not low-risk rats. Neuropsychopharmacology. 2020;45:1251\u201362. https:\/\/doi.org\/10.1038\/s41386-019-0571-9","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR81","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.neubiorev.2021.10.043","volume":"132","author":"RM Brown","year":"2022","unstructured":"Brown RM, Dayas CV, James MH, Smith RJ. New directions in modelling dysregulated reward seeking for food and drugs. Neurosci Biobehav Rev. 2022;132:1037\u201348.","journal-title":"Neurosci Biobehav Rev"},{"key":"3571_CR82","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/npp.2012.37","volume":"37","author":"BA Zimmer","year":"2012","unstructured":"Zimmer BA, Oleson EB, Roberts D. The motivation to self-administer is increased after a history of spiking brain levels of cocaine. Neuropsychopharmacology. 2012;37:1901\u201310.","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR83","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bph.15791","volume":"180","author":"G D\u2019Ottavio","year":"2023","unstructured":"D\u2019Ottavio G, Reverte I, Ragozzino D, Meringolo M, Milella MS, Boix F, et al. Increased heroin intake and relapse vulnerability in intermittent relative to continuous self\u2010administration: sex differences in rats. Br J Pharmacol. 2023;180:910\u201326.","journal-title":"Br J Pharmacol"},{"key":"3571_CR84","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1111\/ejn.14166","volume":"50","author":"MH James","year":"2019","unstructured":"James MH, Bowrey HE, Stopper CM, Aston\u2010Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin\/hypocretin\u20101 receptor antagonist in rats. Eur J Neurosci. 2019;50:2602\u201312.","journal-title":"Eur J Neurosci"},{"key":"3571_CR85","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00213-013-3120-y","volume":"229","author":"JM Bossert","year":"2013","unstructured":"Bossert JM, Marchant NJ, Calu DJ, Shaham Y. The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology. 2013;229:453\u201376.","journal-title":"Psychopharmacology"},{"key":"3571_CR86","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41583-020-0378-z","volume":"21","author":"M Venniro","year":"2020","unstructured":"Venniro M, Banks ML, Heilig M, Epstein DH, Shaham Y. Improving translation of animal models of addiction and relapse by reverse translation. Nat Rev Neurosci. 2020;21:625\u201343.","journal-title":"Nat Rev Neurosci"},{"key":"3571_CR87","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fnbeh.2013.00144","volume":"7","author":"K Qi","year":"2013","unstructured":"Qi K, Wei C, Li Y, Sui N. Orexin receptors within the nucleus accumbens shell mediate the stress but not drug priming-induced reinstatement of morphine conditioned place preference. Front Behav Neurosci. 2013;7:144.","journal-title":"Front Behav Neurosci"},{"key":"3571_CR88","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/adb.12236","volume":"21","author":"SJ Guo","year":"2016","unstructured":"Guo SJ, Cui Y, Huang ZZ, Liu H, Zhang XQ, Jiang JX, et al. Orexin a\u2010mediated AKT signaling in the dentate gyrus contributes to the acquisition, expression and reinstatement of morphine\u2010induced conditioned place preference. Addict Biol. 2016;21:547\u201359.","journal-title":"Addict Biol"},{"key":"3571_CR89","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neulet.2018.12.029","volume":"696","author":"R Azizbeigi","year":"2019","unstructured":"Azizbeigi R, Haghparast A. Involvement of orexin-2 receptor in the ventral tegmental area in stress-and drug priming-induced reinstatement of conditioned place preference in rats. Neurosci Lett. 2019;696:121\u20136.","journal-title":"Neurosci Lett"},{"key":"3571_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109685","volume":"239","author":"JM Illenberger","year":"2023","unstructured":"Illenberger JM, Flores-Ramirez FJ, Pascasio G, Matzeu A, Martin-Fardon R. Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement. Neuropharmacology. 2023;239:109685 https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109685","journal-title":"Neuropharmacology"},{"key":"3571_CR91","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.alcohol.2009.07.002","volume":"43","author":"DE Moorman","year":"2009","unstructured":"Moorman DE, Aston-Jones G. Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol\u2013preferring Sprague\u2013Dawley rats. Alcohol. 2009;43:379\u201386. https:\/\/doi.org\/10.1016\/j.alcohol.2009.07.002","journal-title":"Alcohol"},{"key":"3571_CR92","doi-asserted-by":"publisher","first-page":"109524","DOI":"10.1016\/j.neuropharm.2023.109524","volume":"232","author":"D Ozdemir","year":"2023","unstructured":"Ozdemir D, Allain F, Kieffer BL, Darcq E. Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models. Neuropharmacology. 2023;232:109524.","journal-title":"Neuropharmacology"},{"key":"3571_CR93","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/can.2022.0036","volume":"9","author":"RL Scicluna","year":"2024","unstructured":"Scicluna RL, Wilson BB, Thelaus SH, Arnold JC, McGregor IS, Bowen MT. Cannabidiol reduced the severity of gastrointestinal symptoms of opioid withdrawal in male and female mice. Cannabis Cannabinoid Res. 2024;9:547\u201360.","journal-title":"Cannabis Cannabinoid Res"},{"key":"3571_CR94","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14037","volume":"33","author":"RK Tisdale","year":"2024","unstructured":"Tisdale RK, Sun Y, Park S, Ma SC, Haire M, Allocca G, et al. Biological sex influences sleep phenotype in mice experiencing spontaneous opioid withdrawal. J Sleep Res. 2024;33:e14037.","journal-title":"J Sleep Res"},{"key":"3571_CR95","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/00207454.2020.1802266","volume":"132","author":"M Kourosh-Arami","year":"2021","unstructured":"Kourosh-Arami M, Joghataei M-T, Komaki A, Gholami M, Najafi Z, Lavaie M. Persistent effects of the orexin-1 receptor antagonist SB-334867 on naloxone precipitated morphine withdrawal symptoms and nociceptive behaviors in morphine dependent rats. Int J Neurosci. 2021;132:67\u201376.","journal-title":"Int J Neurosci"},{"key":"3571_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2023.106080","volume":"151","author":"H Ye","year":"2023","unstructured":"Ye H, Cao T, Shu Q, Chen Y, Lu Y, He Z, et al. Blockade of orexin receptor 1 attenuates morphine protracted abstinence-induced anxiety-like behaviors in male mice. Psychoneuroendocrinology. 2023;151:106080.","journal-title":"Psychoneuroendocrinology"},{"key":"3571_CR97","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neulet.2016.02.022","volume":"617","author":"M Davoudi","year":"2016","unstructured":"Davoudi M, Azizi H, Mirnajafi-Zadeh J, Semnanian S. The blockade of GABAA receptors attenuates the inhibitory effect of orexin type 1 receptors antagonist on morphine withdrawal syndrome in rats. Neurosci Lett. 2016;617:201\u20136.","journal-title":"Neurosci Lett"},{"key":"3571_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2013.10.064","volume":"558","author":"SM Ahmadi-Soleimani","year":"2014","unstructured":"Ahmadi-Soleimani SM, Ghaemi-Jandabi M, Azizi H, Semnanian S. Orexin type 1 receptor antagonism in Lateral Paragigantocellularis nucleus attenuates naloxone precipitated morphine withdrawal symptoms in rats. Neurosci Lett. 2014;558:62\u201366.","journal-title":"Neurosci Lett"},{"key":"3571_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pbb.2017.06.001","volume":"158","author":"M Hooshmandi","year":"2017","unstructured":"Hooshmandi M, Hosseinmardi N, Janahmadi M, Khakpai F, Rohampour K, Doostmohammadi J. Antagonism of orexin type-1 receptors (OX1Rs) attenuates naloxone-precipitated morphine withdrawal syndrome in rat dorsal hippocampus. Pharmacol Biochem Behav. 2017;158:39\u201348.","journal-title":"Pharmacol Biochem Behav"},{"key":"3571_CR100","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.neulet.2016.10.051","volume":"636","author":"B Hooshmand","year":"2017","unstructured":"Hooshmand B, Azizi H, Javan M, Semnanian S. Intra-LC microinjection of orexin type-1 receptor antagonist SB-334867 attenuates the expression of glutamate-induced opiate withdrawal like signs during the active phase in rats. Neurosci Lett. 2017;636:276\u201381. https:\/\/doi.org\/10.1016\/j.neulet.2016.10.051","journal-title":"Neurosci Lett"},{"key":"3571_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114441","volume":"448","author":"ML Bedard","year":"2023","unstructured":"Bedard ML, Lord JS, Perez PJ, Bravo IM, Teklezghi AT, Tarantino LM, et al. Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL\/6J mice. Behav Brain Res. 2023;448:114441.","journal-title":"Behav Brain Res"},{"key":"3571_CR102","doi-asserted-by":"publisher","first-page":"361054","DOI":"10.1093\/ecam\/nep133","volume":"2011","author":"Y-J Li","year":"2011","unstructured":"Li Y-J, Zhong F, Yu P, Han J-S, Cui C-L, Wu L-Z. Electroacupuncture treatment normalized sleep disturbance in morphine withdrawal rats. Evid Based Complement Alternat Med. 2011;2011:361054.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3571_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/01677063.2011.566953","volume":"25","author":"CJ Winrow","year":"2011","unstructured":"Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, et al. Promotion of sleep by suvorexant\u2014a novel dual orexin receptor antagonist. J Neurogenet. 2011;25:52\u201361.","journal-title":"J Neurogenet"},{"key":"3571_CR104","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fnins.2013.00235","volume":"7","author":"D Hoyer","year":"2013","unstructured":"Hoyer D, D\u00fcrst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, et al. Distinct effects of IPSU and suvorexant on mouse sleep architecture. Front Neurosci. 2013;7:235.","journal-title":"Front Neurosci"},{"key":"3571_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/srep27147","volume":"6","author":"AL Gotter","year":"2016","unstructured":"Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, et al. Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. Sci Rep. 2016;6:27147.","journal-title":"Sci Rep"},{"key":"3571_CR106","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41386-023-01679-0","volume":"49","author":"AS Huhn","year":"2024","unstructured":"Huhn AS, Dunn KE. The orexin neurotransmitter system as a target for medication development for opioid use disorder. Neuropsychopharmacology. 2024;49:329\u201330. https:\/\/doi.org\/10.1038\/s41386-023-01679-0","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR107","doi-asserted-by":"publisher","first-page":"e30093","DOI":"10.1097\/md.0000000000030093","volume":"101","author":"WR You","year":"2022","unstructured":"You WR, Lin LC, Lin WC, Tsai MC. Differences in orexin-A level in the functional brain network of HUD patients undergoing harm reduction therapy. Medicine. 2022;101:e30093. https:\/\/doi.org\/10.1097\/md.0000000000030093","journal-title":"Medicine"},{"key":"3571_CR108","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307\u201349. https:\/\/doi.org\/10.5664\/jcsm.6470","journal-title":"J Clin Sleep Med"},{"key":"3571_CR109","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.smrv.2011.03.004","volume":"16","author":"BP Hasler","year":"2012","unstructured":"Hasler BP, Smith LJ, Cousins JC, Bootzin RR. Circadian rhythms, sleep, and substance abuse. Sleep Med Rev. 2012;16:67\u201381. https:\/\/doi.org\/10.1016\/j.smrv.2011.03.004","journal-title":"Sleep Med Rev"},{"key":"3571_CR110","doi-asserted-by":"publisher","first-page":"e0304461","DOI":"10.1371\/journal.pone.0304461","volume":"19","author":"AM White","year":"2024","unstructured":"White AM, Eglovitch M, Parlier-Ahmad AB, Dzierzewski JM, James M, Bjork JM, et al. Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder. PLoS One. 2024;19:e0304461.","journal-title":"PLoS One"},{"key":"3571_CR111","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41386-022-01356-8","volume":"48","author":"R Guo","year":"2023","unstructured":"Guo R, Vaughan DT, Rojo ALA, Huang YH. Sleep-mediated regulation of reward circuits: implications in substance use disorders. Neuropsychopharmacology. 2023;48:61\u201378. https:\/\/doi.org\/10.1038\/s41386-022-01356-8","journal-title":"Neuropsychopharmacology"},{"key":"3571_CR112","doi-asserted-by":"crossref","unstructured":"Fragale, J. E., M. H. James, J. A. Avila, A. M. Spaeth, R. N. Aurora, D. Langleben and G. Aston-ones. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System. Front Neurol Neurosci. 2021;45:117\u2013127","DOI":"10.1159\/000514965"},{"key":"3571_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146359","volume":"1731","author":"R Suchting","year":"2020","unstructured":"Suchting R, Yoon JH, Miguel GGS, Green CE, Weaver MF, Vincent JN, et al. Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Res. 2020;1731:146359. https:\/\/doi.org\/10.1016\/j.brainres.2019.146359","journal-title":"Brain Res"},{"key":"3571_CR114","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/fbp.0000000000000731","volume":"34","author":"JC Strickland","year":"2023","unstructured":"Strickland JC, Hatton KW, Hays LR, Rayapati AO, Lile JA, Rush CR, et al. Use of drug purchase tasks in medications development research: orexin system regulation of cocaine and drug demand. Behav Pharmacol. 2023;34:275\u201386. https:\/\/doi.org\/10.1097\/fbp.0000000000000731","journal-title":"Behav Pharmacol"},{"key":"3571_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173466","volume":"220","author":"WW Stoops","year":"2022","unstructured":"Stoops WW, Strickland JC, Hatton KW, Hays LR, Rayapati AO, Lile JA, et al. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans. Pharmacol Biochem Behav. 2022;220:173466. https:\/\/doi.org\/10.1016\/j.pbb.2022.173466","journal-title":"Pharmacol Biochem Behav"},{"key":"3571_CR116","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/7854_2015_391","volume":"27","author":"PJ Meyer","year":"2016","unstructured":"Meyer PJ, King CP, Ferrario CR. Motivational processes underlying substance abuse disorder. Curr Top Behav Neurosci. 2016;27:473\u2013506. https:\/\/doi.org\/10.1007\/7854_2015_391","journal-title":"Curr Top Behav Neurosci"},{"key":"3571_CR117","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/ajad.12862","volume":"28","author":"TR Kosten","year":"2019","unstructured":"Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28:55\u201362. https:\/\/doi.org\/10.1111\/ajad.12862","journal-title":"Am J Addict"},{"key":"3571_CR118","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/10550490902925920","volume":"18","author":"TF Newton","year":"2009","unstructured":"Newton TF, De La Garza R 2nd, Kalechstein AD, Tziortzis D, Jacobsen CA. Theories of addiction: methamphetamine users\u2019 explanations for continuing drug use and relapse. Am J Addict. 2009;18:294\u2013300. https:\/\/doi.org\/10.1080\/10550490902925920","journal-title":"Am J Addict"},{"key":"3571_CR119","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","volume":"6","author":"J Strang","year":"2020","unstructured":"Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nat Rev Dis Prim. 2020;6:3. https:\/\/doi.org\/10.1038\/s41572-019-0137-5","journal-title":"Nat Rev Dis Prim"},{"key":"3571_CR120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jsat.2016.11.003","volume":"73","author":"SP Stumbo","year":"2017","unstructured":"Stumbo SP, Yarborough BJ, McCarty D, Weisner C, Green CA. Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement. J Subst Abuse Treat. 2017;73:47\u201354. https:\/\/doi.org\/10.1016\/j.jsat.2016.11.003","journal-title":"J Subst Abuse Treat"},{"key":"3571_CR121","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pain.2008.03.021","volume":"139","author":"TJ Cicero","year":"2008","unstructured":"Cicero TJ, Lynskey M, Todorov A, Inciardi JA, Surratt HL. Co-morbid pain and psychopathology in males and females admitted to treatment for opioid analgesic abuse. Pain. 2008;139:127\u201335. https:\/\/doi.org\/10.1016\/j.pain.2008.03.021","journal-title":"Pain"},{"key":"3571_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.112650","volume":"391","author":"SM Ahmadi-Soleimani","year":"2020","unstructured":"Ahmadi-Soleimani SM, Mianbandi V, Azizi H, Azhdari-Zarmehri H, Ghaemi-Jandabi M, Abbasi-Mazar A, et al. Coregulation of sleep-pain physiological interplay by orexin system: an unprecedented review. Behav Brain Res. 2020;391:112650. https:\/\/doi.org\/10.1016\/j.bbr.2020.112650","journal-title":"Behav Brain Res"},{"key":"3571_CR123","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/sleep\/29.2.145","volume":"29","author":"T Roehrs","year":"2006","unstructured":"Roehrs T, Hyde M, Blaisdell B, Greenwald M, Roth T. Sleep loss and REM sleep loss are hyperalgesic. Sleep. 2006;29:145\u201351. https:\/\/doi.org\/10.1093\/sleep\/29.2.145","journal-title":"Sleep"},{"key":"3571_CR124","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.pain.2013.04.046","volume":"154","author":"S Schuh-Hofer","year":"2013","unstructured":"Schuh-Hofer S, Wodarski R, Pfau DB, Caspani O, Magerl W, Kennedy JD, et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: a surrogate pain model to study the relationship of insomnia and pain. Pain. 2013;154:1613\u201321. https:\/\/doi.org\/10.1016\/j.pain.2013.04.046","journal-title":"Pain"},{"key":"3571_CR125","doi-asserted-by":"publisher","first-page":"e0225849","DOI":"10.1371\/journal.pone.0225849","volume":"14","author":"AT Staffe","year":"2019","unstructured":"Staffe AT, Bech MW, Clemmensen SLK, Nielsen HT, Larsen DB, Petersen KK. Total sleep deprivation increases pain sensitivity, impairs conditioned pain modulation and facilitates temporal summation of pain in healthy participants. PLoS One. 2019;14:e0225849. https:\/\/doi.org\/10.1371\/journal.pone.0225849","journal-title":"PLoS One"},{"key":"3571_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101467","volume":"57","author":"Y Sun","year":"2021","unstructured":"Sun Y, Laksono I, Selvanathan J, Saripella A, Nagappa M, Pham C, et al. Prevalence of sleep disturbances in patients with chronic non-cancer pain: a systematic review and meta-analysis. Sleep Med Rev. 2021;57:101467. https:\/\/doi.org\/10.1016\/j.smrv.2021.101467","journal-title":"Sleep Med Rev"},{"key":"3571_CR127","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/204946370800200102","volume":"2","author":"NK Tang","year":"2008","unstructured":"Tang NK. Insomnia co-occurring with chronic pain: clinical features, interaction, assessments and possible interventions. Rev Pain. 2008;2:2\u20137. https:\/\/doi.org\/10.1177\/204946370800200102","journal-title":"Rev Pain"},{"key":"3571_CR128","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.sleep.2021.05.021","volume":"84","author":"AK Wilkerson","year":"2021","unstructured":"Wilkerson AK, McRae-Clark AL. A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem. Sleep Med. 2021;84:142\u201353. https:\/\/doi.org\/10.1016\/j.sleep.2021.05.021","journal-title":"Sleep Med"},{"key":"3571_CR129","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.biopha.2017.03.053","volume":"90","author":"BM Razavi","year":"2017","unstructured":"Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation. Biomed Pharmacother. 2017;90:187\u201393. https:\/\/doi.org\/10.1016\/j.biopha.2017.03.053","journal-title":"Biomed Pharmacother"},{"key":"3571_CR130","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1515\/biol-2021-0001","volume":"16","author":"X Kang","year":"2021","unstructured":"Kang X, Tang H, Liu Y, Yuan Y, Wang M. Research progress on the mechanism of orexin in pain regulation in different brain regions. Open Life Sci. 2021;16:46\u201352.","journal-title":"Open Life Sci"},{"key":"3571_CR131","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.brainresbull.2022.07.011","volume":"188","author":"P Chavan","year":"2022","unstructured":"Chavan P, Chikahisa S, Shiuchi T, Shimizu N, Dalanon J, Okura K, et al. Dual orexin receptor antagonist drug suvorexant can help in amelioration of predictable chronic mild stress-induced hyperalgesia. Brain Res Bull. 2022;188:39\u201346.","journal-title":"Brain Res Bull"},{"key":"3571_CR132","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","volume":"74","author":"J Hoffmann","year":"2015","unstructured":"Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, et al. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis. 2015;74:137\u201343.","journal-title":"Neurobiol Dis"},{"key":"3571_CR133","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5664\/jcsm.8220","volume":"16","author":"T Roehrs","year":"2020","unstructured":"Roehrs T, Withrow D, Koshorek G, Verkler J, Bazan L, Roth T. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo. J Clin Sleep Med. 2020;16:415\u201321. https:\/\/doi.org\/10.5664\/jcsm.8220","journal-title":"J Clin Sleep Med"},{"key":"3571_CR134","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/pm\/pnad126","volume":"25","author":"K Ueno","year":"2023","unstructured":"Ueno K, Hitoaki S, Nomura Y, Obata N, Satoshi M. Improvement of sleep and pain with lemborexant administration in patients with chronic pain: a Retrospective Observational Study. Pain Med. 2023;25:139\u201343. https:\/\/doi.org\/10.1093\/pm\/pnad126","journal-title":"Pain Med"},{"key":"3571_CR135","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0333102414544979","volume":"35","author":"A Chabi","year":"2015","unstructured":"Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia. 2015;35:379\u201388. https:\/\/doi.org\/10.1177\/0333102414544979","journal-title":"Cephalalgia"},{"key":"3571_CR136","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","volume":"100","author":"D Muthulingam","year":"2019","unstructured":"Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: a needs assessment for decision making support. J Subst Abuse Treat. 2019;100:18\u201328. https:\/\/doi.org\/10.1016\/j.jsat.2019.01.019","journal-title":"J Subst Abuse Treat"},{"key":"3571_CR137","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","volume":"16","author":"C Muehlan","year":"2020","unstructured":"Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16:1063\u201378. https:\/\/doi.org\/10.1080\/17425255.2020.1817380","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3571_CR138","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.5665\/sleep.5168","volume":"38","author":"A Vermeeren","year":"2015","unstructured":"Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, et al. On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep. 2015;38:1803\u201313. https:\/\/doi.org\/10.5665\/sleep.5168","journal-title":"Sleep"},{"key":"3571_CR139","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","volume":"233","author":"A Vermeeren","year":"2016","unstructured":"Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, et al. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology. 2016;233:3341\u201351. https:\/\/doi.org\/10.1007\/s00213-016-4375-x","journal-title":"Psychopharmacology"},{"key":"3571_CR140","doi-asserted-by":"publisher","first-page":"24353","DOI":"10.1073\/pnas.1907354116","volume":"116","author":"J Seol","year":"2019","unstructured":"Seol J, Fujii Y, Park I, Suzuki Y, Kawana F, Yajima K, et al. Distinct effects of orexin receptor antagonist and GABA(A) agonist on sleep and physical\/cognitive functions after forced awakening. Proc Natl Acad Sci USA. 2019;116:24353\u20138. https:\/\/doi.org\/10.1073\/pnas.1907354116","journal-title":"Proc Natl Acad Sci USA"},{"key":"3571_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110166","volume":"108","author":"P Kaufmann","year":"2021","unstructured":"Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110166. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110166","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3571_CR142","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1177\/0269881118791521","volume":"32","author":"PD van der Ark","year":"2018","unstructured":"van der Ark PD, Golor G, van Nueten L, Nandy P, de Boer P. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J Psychopharmacol. 2018;32:1330\u201340. https:\/\/doi.org\/10.1177\/0269881118791521","journal-title":"J Psychopharmacol"},{"key":"3571_CR143","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/0269881112448946","volume":"26","author":"P Hoever","year":"2012","unstructured":"Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol. 2012;26:1071\u201380. https:\/\/doi.org\/10.1177\/0269881112448946","journal-title":"J Psychopharmacol"},{"key":"3571_CR144","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16:541\u201351. https:\/\/doi.org\/10.1002\/alz.12035","journal-title":"Alzheimers Dement"},{"key":"3571_CR145","doi-asserted-by":"publisher","first-page":"e13902","DOI":"10.1111\/jsr.13902","volume":"32","author":"C Muehlan","year":"2023","unstructured":"Muehlan C, Roch C, Vaillant C, Dingemanse J. The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res. 2023;32:e13902.","journal-title":"J Sleep Res"},{"key":"3571_CR146","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","volume":"94","author":"JM White","year":"1999","unstructured":"White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961\u201372.","journal-title":"Addiction"},{"key":"3571_CR147","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","volume":"125","author":"JD Jones","year":"2012","unstructured":"Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8\u201318.","journal-title":"Drug Alcohol Depend"},{"key":"3571_CR148","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1152\/japplphysiol.00914.2004","volume":"98","author":"JK Young","year":"2005","unstructured":"Young JK, Wu M, Manaye KF, Kc P, Allard JS, Mack SO, et al. Orexin stimulates breathing via medullary and spinal pathways. J Appl Physiol. 2005;98:1387\u201395.","journal-title":"J Appl Physiol"},{"key":"3571_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2022.148061","volume":"1795","author":"I Fukushi","year":"2022","unstructured":"Fukushi I, Yokota S, Takeda K, Terada J, Umeda A, Yoshizawa M, et al. Dual orexin receptor blocker suvorexant attenuates hypercapnic ventilatory augmentation in mice. Brain Res. 2022;1795:148061.","journal-title":"Brain Res"},{"key":"3571_CR150","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/cts.13080","volume":"14","author":"L Xu","year":"2021","unstructured":"Xu L, Krishna A, Stewart S, Shea K, Racz R, Weaver JL, et al. Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat. Clin Transl Sci. 2021;14:2208\u201319.","journal-title":"Clin Transl Sci"},{"key":"3571_CR151","doi-asserted-by":"publisher","first-page":"112434","DOI":"10.1016\/j.drugalcdep.2024.112434","volume":"264","author":"EDC Moreira-Junior","year":"2024","unstructured":"Moreira-Junior EDC, Rowlett JK, Berro LF. Suvorexant enhances oxycodone-induced respiratory depression in male rats. Drug Alcohol Depend. 2024;264:112434.","journal-title":"Drug Alcohol Depend"},{"key":"3571_CR152","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243\u201366.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3571_CR153","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.rmed.2014.12.010","volume":"109","author":"H Sun","year":"2015","unstructured":"Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109:416\u201326.","journal-title":"Respir Med"},{"key":"3571_CR154","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5664\/jcsm.5382","volume":"12","author":"H Sun","year":"2016","unstructured":"Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin sleep Med. 2016;12:9\u201317.","journal-title":"J Clin sleep Med"},{"key":"3571_CR155","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa275","volume":"44","author":"M-L Boof","year":"2021","unstructured":"Boof M-L, Dingemanse J, Lederer K, Fietze I, Ufer M. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep. 2021;44:zsaa275.","journal-title":"Sleep"},{"key":"3571_CR156","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.sleep.2021.11.015","volume":"92","author":"M-L Boof","year":"2022","unstructured":"Boof M-L, Ufer M, Fietze I, Pepin J-L, Guern A-S, Lemoine V, et al. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea. Sleep Med. 2022;92:4\u201311.","journal-title":"Sleep Med"},{"key":"3571_CR157","doi-asserted-by":"publisher","first-page":"e13021","DOI":"10.1111\/jsr.13021","volume":"29","author":"JY Cheng","year":"2020","unstructured":"Cheng JY, Filippov G, Moline M, Zammit GK, Bsharat M, Hall N. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double\u2010blind, placebo\u2010controlled, crossover study. J sleep Res. 2020;29:e13021.","journal-title":"J sleep Res"},{"key":"3571_CR158","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jcph.523","volume":"55","author":"N Uemura","year":"2015","unstructured":"Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, et al. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol. 2015;55:1093\u20131100.","journal-title":"J Clin Pharmacol"},{"key":"3571_CR159","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fpsyt.2018.00450","volume":"9","author":"JC Tolentino","year":"2018","unstructured":"Tolentino JC, Schmidt SL. DSM-5 criteria and depression severity: implications for clinical practice. Front Psychiatry. 2018;9:450. https:\/\/doi.org\/10.3389\/fpsyt.2018.00450","journal-title":"Front Psychiatry"},{"key":"3571_CR160","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","volume":"24","author":"A Savitz","year":"2021","unstructured":"Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study. Int J Neuropsychopharmacol. 2021;24:965\u201376. https:\/\/doi.org\/10.1093\/ijnp\/pyab050","journal-title":"Int J Neuropsychopharmacol"},{"key":"3571_CR161","doi-asserted-by":"publisher","first-page":"pyw022","DOI":"10.1093\/ijnp\/pyw022","volume":"19","author":"KM Connor","year":"2016","unstructured":"Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, et al. A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia. Int J Neuropsychopharmacol. 2016;19:pyw022. https:\/\/doi.org\/10.1093\/ijnp\/pyw022","journal-title":"Int J Neuropsychopharmacol"},{"key":"3571_CR162","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0269881118822258","volume":"33","author":"S Brooks","year":"2019","unstructured":"Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol. 2019;33:202\u20139. https:\/\/doi.org\/10.1177\/0269881118822258","journal-title":"J Psychopharmacol"},{"key":"3571_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0553-z","volume":"9","author":"K Recourt","year":"2019","unstructured":"Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry. 2019;9:216. https:\/\/doi.org\/10.1038\/s41398-019-0553-z","journal-title":"Transl Psychiatry"},{"key":"3571_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02090-x","volume":"12","author":"SM Gorka","year":"2022","unstructured":"Gorka SM, Khorrami KJ, Manzler CA, Phan KL. Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety. Transl Psychiatry. 2022;12:308. https:\/\/doi.org\/10.1038\/s41398-022-02090-x","journal-title":"Transl Psychiatry"},{"key":"3571_CR165","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/24734306.2019.1577535","volume":"3","author":"JL Russell","year":"2019","unstructured":"Russell JL, Spiller HA. Retrospective assessment of toxicity following exposure to orexin pathway modulators modafinil and suvorexant. Toxicol Commun. 2019;3:33\u201336.","journal-title":"Toxicol Commun"},{"key":"3571_CR166","doi-asserted-by":"publisher","first-page":"e14329","DOI":"10.7759\/cureus.14329","volume":"13","author":"H Ito","year":"2021","unstructured":"Ito H, Ogawa Y, Shimojo N, Kawano S. Suvorexant poisoning in a patient with cirrhosis and renal failure. Cureus. 2021;13:e14329 https:\/\/doi.org\/10.7759\/cureus.14329","journal-title":"Cureus"},{"key":"3571_CR167","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-pharmtox-011613-135923","volume":"54","author":"R Dallmann","year":"2014","unstructured":"Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol. 2014;54:339\u201361. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011613-135923","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3571_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101714","volume":"67","author":"S Khoshnevis","year":"2023","unstructured":"Khoshnevis S, Smolensky MH, Haghayegh S, Castriotta RJ, Hermida RC, Diller KR. Recommended timing of medications that impact sleep and wakefulness: a review of the American Prescribers\u2019 digital reference. Sleep Med Rev. 2023;67:101714 https:\/\/doi.org\/10.1016\/j.smrv.2022.101714","journal-title":"Sleep Med Rev"},{"key":"3571_CR169","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/2042098615595359","volume":"6","author":"DN Rhyne","year":"2015","unstructured":"Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf. 2015;6:189\u201395. https:\/\/doi.org\/10.1177\/2042098615595359","journal-title":"Ther Adv Drug Saf"},{"key":"3571_CR170","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","volume":"13","author":"D Michelson","year":"2014","unstructured":"Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:461\u201371. https:\/\/doi.org\/10.1016\/S1474-4422(14)70053-5","journal-title":"Lancet Neurol"},{"key":"3571_CR171","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","volume":"79","author":"WJ Herring","year":"2016","unstructured":"Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in patients with insomnia: results from two 3-month Randomized Controlled Clinical Trials. Biol Psychiatry. 2016;79:136\u201348. https:\/\/doi.org\/10.1016\/j.biopsych.2014.10.003","journal-title":"Biol Psychiatry"},{"key":"3571_CR172","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/jcp.0000000000000516","volume":"36","author":"KA Schoedel","year":"2016","unstructured":"Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, et al. Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study. J Clin Psychopharmacol. 2016;36:314\u201323. https:\/\/doi.org\/10.1097\/jcp.0000000000000516","journal-title":"J Clin Psychopharmacol"},{"key":"3571_CR173","doi-asserted-by":"publisher","first-page":"zsab224","DOI":"10.1093\/sleep\/zsab224","volume":"45","author":"M Ufer","year":"2022","unstructured":"Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep. 2022;45:zsab224 https:\/\/doi.org\/10.1093\/sleep\/zsab224","journal-title":"Sleep"},{"key":"3571_CR174","doi-asserted-by":"publisher","first-page":"809","DOI":"10.5664\/jcsm.9724","volume":"18","author":"AS Tubbs","year":"2022","unstructured":"Tubbs AS, Ghani SB, Naps M, Grandner MA, Stein MD, Chakravorty S. Past-year use or misuse of an opioid is associated with use of a sedative-hypnotic medication: a US National Survey on Drug Use and Health (NSDUH) study. J Clin Sleep Med. 2022;18:809\u201316. https:\/\/doi.org\/10.5664\/jcsm.9724","journal-title":"J Clin Sleep Med"},{"key":"3571_CR175","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.biopsych.2022.06.006","volume":"92","author":"R Guo","year":"2022","unstructured":"Guo R, Wang Y, Yan R, Chen B, Ding W, Gorczyca MT, et al. Rapid eye movement sleep engages melanin-concentrating hormone neurons to reduce cocaine seeking. Biol Psychiatry. 2022;92:880\u201394.","journal-title":"Biol Psychiatry"},{"key":"3571_CR176","doi-asserted-by":"publisher","first-page":"13300","DOI":"10.1523\/JNEUROSCI.1065-15.2015","volume":"35","author":"B Chen","year":"2015","unstructured":"Chen B, Wang Y, Liu X, Liu Z, Dong Y, Huang YH. Sleep regulates incubation of cocaine craving. J Neurosci. 2015;35:13300\u201310.","journal-title":"J Neurosci"},{"key":"3571_CR177","unstructured":"Wiskerke et al. Brain Research. 2020 https:\/\/pubmed.ncbi.nlm.nih.gov\/31002819\/"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03571-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03571-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03571-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:03:21Z","timestamp":1761321801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03571-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3571"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03571-5","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSR and RDV declare no competing financial interests. MHJ is an inventor on US Patent submissions PCT\/US23\/27918 and 63\/601,522. JP is a consultant for Delix Therapeutics, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}